Study objective: To determine whether there is an association between the use of hormonal replacement therapy (HRT) and the risk of stroke and myocardial infarction (MI). Design 
[RR] 1.36, 95% confidence interval [CI] 1.01-1.81). There was a stronger association with preparations contained progestogen alone (RR 1.90, 95% CI 1.1 1-3.25). On average, HRT had been used 9 years before recruitment to the study and for 15 months. However, the observed gradients of risk according to the duration of HRT use and time since HRT use do not support a causal interpretation. Also, the.estimated relative risks were reduced when allowance was made for other cardiovascular risk factors. Conclusions: There is no evidence that the use of HRT as recently prescribed in the UK constitutes a major cardiovascular risk or benefit.
Current evidence about the potential risks of cardiovascular disease (CVD) resulting from the use of hormonal replacement therapy (HRT) is equivocal. Evidence suggesting that oestrogen reduces CVD risks includes the lower risk of CVD in premenopausal women compared to postmenopausal women of the same age' and the increased CVD risk associated with a surgical menopause.2 3 However, oestrogen has an adverse effect-on the risk of CVD in other situations, for example in women using oral contraceptives4 and in men receiving oestrogen therapy.5-7 Direct evidence on the CVD risks associated with the use of noncontraceptive oestrogen has come from both prospective and case-control epidemiological studies. However, the results ofsome ofthe most recent studies have been in conflict with each other8 in showing a reduction in risk9 or an increase in risk.'0 Most of the epidemiological studies yet available have primarily investigated HRT containing oestrogen alone. HRT containing progestogen alone, or combined oestrogen and progestogen, has received little attention and may have different effects. For example, some studies have suggested that the progestogenic component of oral contraceptives may increase the risk of stroke and ischaemic heart disease." 12 Also, as the epidemiological studies performed so far have been mainly based in the USA, the relevance of these to women in the UK is uncertain. For example, the ages of women receiving HRT, the doses and schedules used and, in particular, the duration of HRT use may be substantially different in the UK than in the USA. The use of combined preparations in the UK has been increasing 174 over the past few years following the reduction in the late 1970s in the use of unopposed oestrogen, which was shown to increase the risk of endometrial cancer. 13
The case-control study described here was planned with these considerations in mind. The aim was to investigate the association between the use of HRT, both overall and separately according to progestogen and oestrogen content, and the incidence ofstroke and myocardial infarction (MI) in women aged 45-69 years in the UK. It was decided to base the study in general practice, since those data would be more representative of HRT use overall than data from special menopause clinics.
Methods
The study was based in 83 of the general practices belonging to the Medical Research Council's General Practice Research Framework.'4 At each practice, cases of fatal or non-fatal stroke or MI in white women aged 45 to 69 were notified to the coordinating centre at Northwick Park. In order to increase the numbers of cases available, the first part of the study, carried out in September 1982, involved the retrospective retrieval ofinformation on such cases for the 1 year period before that date. In the second part of the study, carried out from September 1982 to January 1986, suspected cases were notified to the coordinating centre as they arose. Fatal cases tended not to be fully represented in the first part of the study because the medical notes had often already been returned to the Family Practitioner Committees.
The The two controls were caucasian women matched to the case for age (to within 2 years) and for general practitioner. The controls were selected by working through the age/sex register, starting from the name of the case patient, taking the first eligible older and the first eligible younger patient. It was also a requirement, for both cases and controls, that the medical notes for their adult life were complete.
After about 250 cases had been recruited, a formal assessment of the power of the study (taking into account only the rate of ever use of HRT observed in controls at that time) led to the decision to recruit a total of about 600 cases in all. It was estimated that a study of 600 cases (and 1200 controls) would have a power of about 85% to detect, as significant at the 5% level, true relative risks associated with ever use of any HRT further from unity than 1-4 or 0 7. Such a study would also have a power of about 85% to detect true relative risks associated with the ever use of HRT containing progestogen alone, further from unity than 18 or 0-45.
Specially trained quality control (QC) nurses travelled to each of 83 general practices and checked the progress of the study with the research nurse at the practice. The procedure for the selection of controls was checked for two to four randomly chosen controls at each practice. Of 215 controls checked overall, only four (all in one centre) had been selected in a way likely to invalidate comparability of cases and controls. The controls in this centre were abandoned and new ones sought. The QC nurse also made a c'deck on the abstraction of data from the medical notes, in particular by filling in the section of the form on HRT use. For the women who had been noted to use HRT by either the practice nurse or the QC nurse, 80% of the forms were in agreement, 15% were in disagreement when one of the nurses had noted a single HRT prescription (and the other had noted none), but only 4% were in disagreement when one of the nurses had noted two or more HRT prescriptions. A single HRT prescription would presumably reflect a generally short duration of HRT use by the woman concerned (if she even in fact used the prescription at all). For this reason, and because the quality control exercise revealed that such prescribing was not necessarily detected reliably, it was decided to compare cases and controls with respect to HRT use, which was defined as having received at least two HRT prescriptions.
The relative risks of stroke and MI according to HRT use were estimated using conditional maximum likelihood logistic regression, ' 
Relative risks, relative to the group of women with no HRT prescription, take into account the matched design of the study. 20 In the present study, while 11% of the women overall had been prescribed HRT containing oestrogen alone (on at least two occasions), some 4% and 2% had been prescribed combined oestrogenprogestogen and progestogen alone preparations respectively. Most previous epidemiological studies on cardiovascular disease and the use of postmenopausal HRT are American studies ofpreparations containing oestrogen alone, and mainly concern women who had used HRT for longer or more recently than those in the present study. A number of these studies (of which there have been over 15) have shown protective effects of postmenopausal oestrogen use on the risk of CVD (that is, a relative risk estimate below unity), while a few others have shown near null effects (that is, a relative risk estimate close to unity).2' Only two sources ofdata suggest increased risk. First, two small studies22 23 based on 19 and 17 cases ofnon-fatal MI in the same population gave unrealistically high estimated relative risks of9 3 and 7 5 respectively. The high proportion ofthe cases that were smokers and the large loss of study participants that occurred make the interpretation ofthese studies difficult. Secondly, data from the Framingham Study at first suggested an adverse effect of postmenopausal oestrogen on cardiovascular risk,' 10 but a later reanalysis,24 restricting the outcomes included to non-fatal MIs and fatal coronary heart disease (excluding coronary insufficiency and angina pectoris considered previously), showed a protective effect of oestrogen use in women aged 50-59. Taking this evidence as a whole, therefore, it seems that the use of HRT containing oestrogen alone may quite possibly exert a beneficial effect on cardiovascular risk.2' However, it is not necessarily appropriate to extrapolate from these studies to the use of HRT containing progestogen as prescribed in the UK. The different doses and potencies of oestrogen that have been used in, for example, the treatment of prostatic cancer in men and in oral contraceptives may explain the different and adverse effects ofoestrogen on CVD risk experienced in other situations.
It must be concluded from the present study that there is no evidence that the use of HRT as recently prescribed in the UK constitutes a major cardiovascular risk or benefit. It should be noted that the women who had used HRT in the present study had used it, on average, only for 15 months some 9 years before. More evidence is certainly required on the use of HRT containing progestogen, since the frequency and duration of use of such preparations may well increase over the next few years, particularly as a treatment for postmenopausal osteoporosis. We thank the doctors and nurses in the MRC General Practice Research Framework who participated in this study, and we are very grateful to Professor Hugh Tunstall-Pedoe who undertook the substantial task of assessing the cases of stroke and MI. We are also grateful to Pat O'Kelly for the clerical and data processing work involved in the study.
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